NewAmsterdam Pharma Company N.V. (NAMS) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$64.81M*; Operating income -$64.86M; Depreciation and amortization $59.00K*.
- 2026-03-31: Basis Reported; EBITDA -$58.36M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA -$65.92M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$55.08M*; Operating income -$55.14M; Depreciation and amortization $64.00K*.
Complete source-backed ebitda history.
- Available history
- 2021-12-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$64.81M* | -$64.86M | $59.00K* | $3.70M | -1751.01%* | (m) | -$39.21M* | (m) | $41.67M | $26.89M | (m) |
|---|
| 2026-03-31 | Reported | -$58.36M | (m) | (m) | (m) | -1919.67% | (m) | -$30.60M | (m) | $38.01M | $23.45M | (m) |
|---|
| 2025-12-31 | Reported | -$65.92M | (m) | (m) | (m) | -206003.13% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | -$55.08M* | -$55.14M | $64.00K* | $348.00K | -15827.30%* | (m) | -$32.77M* | (m) | $30.97M | $24.52M | (m) |
|---|
| 2025-06-30 | Reported | -$35.59M* | -$35.63M | $45.00K* | $19.14M | -185.90%* | (m) | -$37.67M* | (m) | $27.52M | $27.26M | (m) |
|---|
| 2025-03-31 | Reported | -$68.87M | (m) | (m) | (m) | -2312.73% | (m) | -$36.47M | (m) | $44.75M | $27.15M | (m) |
|---|
| 2024-12-31 | Reported | -$43.18M | (m) | (m) | (m) | -338.07% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$24.98M* | -$25.00M | $28.00K* | $29.11M | -85.79%* | (m) | -$12.50M* | (m) | $35.70M | $18.41M | -$1.00K |
|---|
| 2024-06-30 | Reported | -$52.56M* | -$52.58M | $19.00K* | $2.28M | -2306.10%* | (m) | -$53.98M* | (m) | $38.38M | $16.48M | (m) |
|---|
| 2024-03-31 | Reported | -$55.47M | (m) | (m) | (m) | -3959.10% | (m) | -$54.60M | (m) | $42.43M | $14.45M | (m) |
|---|
| 2023-12-31 | Reported | -$51.06M | (m) | (m) | (m) | -6358.78% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | -$49.54M* | -$49.56M | $14.00K* | $2.94M | -1684.60%* | (m) | -$46.98M* | (m) | $43.37M | $9.13M | (m) |
|---|
| 2023-06-30 | Reported | -$42.47M* | -$42.48M | $13.00K* | $1.72M | -2473.44%* | (m) | -$29.30M* | (m) | $34.34M | $9.86M | (m) |
|---|
| 2023-03-31 | Reported | -$39.84M | (m) | (m) | (m) | -461.75% | (m) | -$31.86M | (m) | $40.42M | $8.06M | (m) |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | -$225.46M | (m) | (m) | (m) | -1001.92% | (m) | -$147.78M | (m) | $141.83M | $106.35M | (m) |
|---|
| 2024-12-31 | Reported | -$176.18M | (m) | (m) | (m) | -386.66% | (m) | -$158.56M | (m) | $151.41M | $70.45M | -$1.00K |
|---|
| 2023-12-31 | Reported | -$182.92M | (m) | (m) | (m) | -1298.21% | (m) | -$141.22M | (m) | $159.42M | $37.63M | $27.00K |
|---|
| 2022-12-31 | Reported | -$3.55M | (m) | (m) | (m) | -3.45% | (m) | $10.66M | (m) | $86.74M | $19.51M | (m) |
|---|
| 2021-12-31 | Reported | -$34.97M | (m) | (m) | (m) | (m) | (m) | -$29.51M | (m) | $28.97M | $6.00M | (m) |
|---|